Patients facing serious or life-threatening illnesses who are ineligible or unable to participate in a clinical trial and may not have options for alternative therapies, including investigational therapies in trials being conducted by other sponsors, may consider expanded access programs for unapproved therapies.

Please see Prothena’s Expanded Access Policy to determine if Prothena currently offers expanded access to any of our investigational drugs.